Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.52 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamide SCHEMBL27935470 | 0.98 | PARP1 (0.73) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL2401802 | 0.91 | PARP1 (0.76) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL9496452 | 0.88 | PARP1 (0.73) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL27660419 | 0.88 | PARP1 (0.73) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL8687117 | 0.88 | PARP1 (0.73) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL11654359 | 0.88 | PARP1 (0.73) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL27752814 | 0.88 | CYP3A4 (0.80) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL28488657 | 0.88 | PARP1 (0.80) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL2061911 | 0.87 | PARP1 (0.89) | PARP1CYP3A4MAPTTDP1TSHR | |
| Benzamide SCHEMBL28132124 | 0.87 | PARP1 (0.89) | PARP1CYP3A4MAPTTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116791257-A | Stain resistant yarn and carpet made of same | 烟台鑫泰汽车配件有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116791257-A | Stain resistant yarn and carpet made of same | 烟台鑫泰汽车配件有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-101056632-B | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2011-12-07 | — | — | CN | disclosed |
| US-7932421-B2 | diabetes or obesity; polycystic ovarian disease, an eating disorder, craniopharyngioma, Prader-Willi syndrome, Frohlich's syndrome, hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, low HDL levels, high HDL levels, hyperglycemia, insulin resistance, hyperinsulinemia, Cushing's | AMGEN INC. (US) | 2011-04-26 | — | — | US | disclosed |
| CN-100594903-C | HCV inhibitory bicyclic pyrimidines | TIBOTEC PHARM LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2121580-A2 | N-CYCLOHEXYL BENZAMIDES AND BENZENEACETAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASES | Amgen Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080221175-A1 | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases | AMGEN INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008088540-A2 | N-CYCLOHEXYL BENZAMIDES AND BENZENEACETAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| CN-101031304-A | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC PHARM LTD (IE) | 2007-09-05 | — | — | CN | disclosed |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6610837-B1 | Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2000055179-A1 | NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-6121437-A | SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221175-A1 | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases | HSD11B1, HSD3B1, HSD3B2 | PARP1 1928/4885CYP3A4 89/4885MAPT 4648/4885 |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | TYMP, MTAP, PPIP5K2 | PARP1 413/4885CYP3A4 4396/4885MAPT 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.